Compare KRRO & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRRO | SAMG |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 125.5M |
| IPO Year | 2019 | 2012 |
| Metric | KRRO | SAMG |
|---|---|---|
| Price | $14.01 | $13.57 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | ★ 227.5K | 31.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 6.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.56 |
| Revenue | $6,392,000.00 | ★ $91,358,000.00 |
| Revenue This Year | N/A | $12.83 |
| Revenue Next Year | N/A | $3.62 |
| P/E Ratio | ★ N/A | $23.89 |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $13.00 |
| 52 Week High | $55.89 | $16.97 |
| Indicator | KRRO | SAMG |
|---|---|---|
| Relative Strength Index (RSI) | 65.53 | 38.81 |
| Support Level | $13.80 | $13.27 |
| Resistance Level | $14.96 | $15.76 |
| Average True Range (ATR) | 0.88 | 0.65 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 90.36 | 27.55 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.